The American Journal of Medicine
Volume 122, Issue 1, Supplement , Pages S26-S37 , January 2009

“Sick Fat,” Metabolic Disease, and Atherosclerosis

  • Harold E. Bays, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Harold E. Bays, MD, L-MARC Research Center, 3288 Illinois Avenue, Louisville, Kentucky 40213

References 

  1. Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937–952
  2. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143–3421
  3. Bays HE, Rodbard RW, Schorr AB, González-Campoy JM. Adiposopathy: treating pathogenic adipose tissue (adiposopathy) to reduce cardiovascular disease risk. Curr Treat Options Cardiovasc Med. 2007;9:259–271
  4. Bays HE, Gonzalez-Campoy JM, Henry RR, Bergman DA, Kitabchi AE, Schorr AB, et al. Is adiposopathy (sick fat) an endocrine disease?. Int J Clin Pract. 2008;62:1474–1483
  5. Pladevall M, Singal B, Williams LK, et al. A single factor underlies the metabolic syndrome: a confirmatory factor analysis. Diabetes Care. 2006;29:113–122
  6. Stern MP. Diabetes and cardiovascular disease: the “common soil” hypothesis. Diabetes. 1995;44:369–374
  7. Bays H. Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything. Expert Rev Cardiovasc Ther. 2005;3:393–404
  8. Bays HE, Gonzalez-Campoy JM, Bray GA, et al. The pathogenic potential of adipose tissue and the metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther. 2008;6:343–368
  9. Bays H, Ballantyne C. Adiposopathy: why do adiposity and obesity cause metabolic disease?. Future Lipidology. 2006;1:389–420
  10. O'Keefe JH, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142–2146
  11. Dierenfeld ES, Hoppe PP, Woodford MH, Krilov NP, Klimov VV, Yasinetskaya NI. Plasma alpha-tocopherol, beta-carotene, and lipid levels in semi–free-ranging Przewalski horses (Equus prezewalskii). J Zoo Wildl Med. 1997;28:144–147
  12. Vitić J, Stevanović J. Comparative studies of the serum lipoproteins and lipids in some domestic, laboratory and wild animals. Comp Biochem Physiol B. 1993;106:223–229
  13. Lochmiller RL, Grant WE. Serum chemistry of the collared peccary (Tayassu tajacu). J Wildl Dis. 1984;20:134–140
  14. Ghebremeskel K, Williams G, Lewis JC, Du Toit R. Serum alpha-tocopherol, all-trans retinol, total lipids and cholesterol in the black rhinoceros (Diceros bicornis). Comp Biochem Physiol A. 1988;91:343–345
  15. Dillman JS, Car WR. Observations on arteriosclerosis, serum cholesterol and serum electrolytes in the wild African elephant (Loxodonta africana). J Comp Pathol. 1970;80:81–87
  16. Kemnitz JW, Sapolsky RM, Altmann J, Muruthi P, Mott GE, Stefanick ML. Effects of food availability on serum insulin and lipid concentrations in free-ranging baboons. Am J Primatol. 2002;57:13–19
  17. Vié JC, Moreau B, de Thoisy B, Fournier P, Genty C. Hematology and serum biochemistry values of free-ranging red howler monkeys (Alouatta seniculus) from French Guiana. J Zoo Wildl Med. 1998;29:142–149
  18. Clark SB, Tercyak AM, Glander KE. Plasma lipoproteins of free-ranging howling monkeys (Alouatta palliata). Comp Biochem Physiol B. 1987;88:729–735
  19. Malaga CA, Weller RE, Buschbom RL, Ragan HA. Serum chemistry of the wild caught karyotype I night monkey (Aotus nancymai). Lab Anim Sci. 1991;41:143–145
  20. Barnicot NA, Bennett FJ, Woodburn JC, Pilkington TR, Antonis A. Blood pressure and serum cholesterol in the Hadza of Tanzania. Hum Biol. 1972;44:87–116
  21. Corcoran AC, Rabinowitch IM. A study of the blood lipoids and blood protein in Canadian Eastern Arctic Eskimos. Biochem J. 1937;31:343–348
  22. Truswell AS. Diet and nutrition of hunter-gatherers. Ciba Found Symp. 1977;213–221
  23. Mann GV, Roels OA, Price DL, Merrill JM. Cardiovascular disease in African Pygmies: a survey of the health status, serum lipids and diet of Pygmies in Congo. J Chronic Dis. 1962;15:341–371
  24. Wilmsen EN. Seasonal effects of dietary intake on Kalahari San. Fed Proc. 1978;37:65–72
  25. Eberhardt MS, Ingram DD, Makuc DM. Urban and Rural Chartbook: Health in the United States, 2001. Hyattsville, MD: National Center for Health Statistics; 2001;DHS Publication No. 01-1232
  26. Bays HE, Chapman RH, Grandy S. The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys. Int J Clin Pract. 2007;61:737–747
  27. World Health Organization. Global strategy on diet, physical activity and health. http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/Accessed January 4, 2008
  28. Balkau B, Shipley M, Jarrett RJ, Pyörälä K, Pyörälä M, Forhan A, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21:360–367
  29. Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW. Glycemic control and coronary heart disease risk in persons with and without diabetes: the Atherosclerosis Risk in Communities study. Arch Intern Med. 2005;165:1910–1916
  30. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Arterioscler Thromb Vasc Biol. 1999;19:1014–1019
  31. Howard BV, Best LG, Galloway JM, et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care. 2006;29:391–397
  32. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653
  33. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  34. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007;49:1772–1780
  35. National Heart, Lung, and Blood Institute. For safety, NHLBI changes intensive blood sugar treatment strategy in clinical trial of diabetes and cardiovascular disease [news release on ACCORD Trial]. February 6, 2008. http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2551Accessed February 14, 2008
  36. Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) trial Web site (Major international diabetes study does not confirm increased risk of death reported by US trial: preliminary findings from the largest-ever study of treatments for diabetes provide no evidence that intensive treatment to lower blood glucose (sugar) increases risk of death [news release]. February 13, 2008). http://www.advance-trial.com/static/html/virtual/contents.asp?P=39Accessed March 13, 2008
  37. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, et al. Prospective Studies Collaboration Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913
  38. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291–1297
  39. National High Blood Pressure Education Program JNC 7 Express. The Seventh Report of the Joint National Committee on Prevention, Evaluation, and Treatment of High Blood Pressure. www.nhlbi.nih.gov/guidelines/hypertension/express.pdfAccessed January 4, 2008
  40. Bays HE, McGovern ME. Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin. Prev Cardiol. 2005;8:226–233
  41. Bays H, McKenney J, Davidson M. Torcetrapib/atorvastatin combination therapy. Expert Rev Cardiovasc Ther. 2005;3:789–820
  42. Schaefer EJ, Asztalos BF. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction. Am J Cardiol. 2007;100(suppl 1):S25–S31
  43. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  44. American Diabetes Association. Executive summary: standards of medical care in diabetes—2008. Diabetes Care. 2008;31:S5–S11Available at: http://care.diabetesjournals.org/cgi/reprint/31/Supplement_1/S5. Accessed April 8, 2008
  45. Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association and the National Heart, Lung, and Blood Institute Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–2752
  46. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal (Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes). Diabetes Care. 2005;28:2289–2304
  47. Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know?. J Clin Endocrinol Metab. 2004;89:2569–2575
  48. Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure, and dyslipidemia. Future Cardiology. 2005;1:39–59
  49. Bays H, Blonde L, Rosenson R. Adiposopathy: how do diet, exercise, weight loss and drug therapies improve metabolic disease?. Expert Rev Cardiovasc Ther. 2006;4:871–895
  50. Gavrilova O, Marcus-Samuels B, Graham D, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest. 2000;105:271–278
  51. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator–activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89:463–478
  52. Oreopoulos A, Padwal R, Norris CM, Mullen JC, Pretorius V, Kalantar-Zadeh K. Effect of obesity on short- and long-term mortality postcoronary revascularization: a meta-analysis. Obesity. 2008;16:442–450
  53. Kushner RF, Roth JL. Assessment of the obese patient. Endocrinol Metab Clin North Am. 2003;32:915–933
  54. Higuchi ML, Gutierrez PS, Bezerra HG, et al. Comparison between adventitial and intimal inflammation of ruptured and nonruptured atherosclerotic plaques in human coronary arteries. Arq Bras Cardiol. 2002;79:20–24
  55. Storlien L, Oakes ND, Kelley DE. Metabolic flexibility. Proc Nutr Soc. 2004;63:363–368
  56. Adams JM, Pratipanawatr T, Berria R, Wang E, DeFronzo RA, Sullards MC, et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes. 2004;53:25–31
  57. Chavez JA, Holland WL, Bär J, Sandhoff K, Summers SA. Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling. J Biol Chem. 2005;280:20148–20153
  58. Kelley DE, Goodpaster BH. Skeletal muscle triglyceride: an aspect of regional adiposity and insulin resistance. Diabetes Care. 2001;24:933–941
  59. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes. 2000;49:677–683
  60. Grill V, Persson G, Carlsson S, et al. Family history of diabetes in middle-aged Swedish men is a gender unrelated factor which associates with insulinopenia in newly diagnosed diabetic subjects. Diabetologia. 1999;42:15–23
  61. Higuchi ML, Gutierrez PS, Bezerra HG, et al. Comparison between adventitial and intimal inflammation of ruptured and nonruptured atherosclerotic plaques in human coronary arteries. Arq Bras Cardiol. 2002;79:20–24
  62. Bays H. Adiposopathy: the endocannabinoid system as a therapeutic treatment target for dysfunctional “sick” fat. California Journal of Health System Pharmacy. 2007;19:32–39
  63. Bays H. The melanocortin system as a therapeutic treatment target for adiposity and adiposopathy. Drugs R D. 2006;7:289–302
  64. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741–749

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

 To access a slide kit for this article, please click here.

PII: S0002-9343(08)01019-X

doi: 10.1016/j.amjmed.2008.10.015

The American Journal of Medicine
Volume 122, Issue 1, Supplement , Pages S26-S37 , January 2009

Article Tools

* Image Usage & Resolution